PhRMA spent almost $10 million lobbying to stop legislation to help generic companies

Faced with pressure from President Donald Trump’s administration and lawmakers on drug pricing, generic medicines and trade, the drug industry set quarterly records for lobbying spending in the first three months of 2018. According to disclosures filed with the government, the Pharmaceutical Research and Manufacturers of American spent $9.96 million on federal lobbying. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.